{"id":111681,"date":"2026-01-05T19:52:10","date_gmt":"2026-01-05T19:52:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-tx\/111681\/"},"modified":"2026-01-05T19:52:10","modified_gmt":"2026-01-05T19:52:10","slug":"how-an-electrical-engineer-is-making-a-big-impact-on-cancer-research","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-tx\/111681\/","title":{"rendered":"How an electrical engineer is making a big impact on cancer research"},"content":{"rendered":"<p><a href=\"http:\/\/faculty.mdanderson.org\/profiles\/xiling_shen.html\" target=\"_self\" rel=\"nofollow noopener\">Xiling Shen, Ph.D.<\/a>, was an electrical engineering professor when a landmark discovery prompted him to shift the focus of his work and dedicate his lab to <a href=\"https:\/\/www.mdanderson.org\/treatment-options\/targeted-therapy.html\" target=\"_self\" rel=\"nofollow noopener\">precision medicine<\/a>.<\/p>\n<p>Throughout his life, Shen had felt the pull of medicine. As a high school student in Shanghai, he dreamed of becoming a doctor. But when he was in high school, he lost his uncle to <a href=\"https:\/\/www.mdanderson.org\/cancer-types\/colorectal-cancer.html\" target=\"_self\" rel=\"nofollow noopener\">colorectal cancer<\/a>. Watching his uncle suffer caused Shen to fear that a career as a physician would have too great of an emotional toll.<\/p>\n<p>\u201cI chose to be an electrical engineer, so I only needed to deal with machines,\u201d he says.<\/p>\n<p>He designed electrical circuits for wireless semiconductor chips at both a Silicon Valley startup and more established companies. He also studied optical communication via multimode fibers. But over the years, he began to contemplate understanding complex gene regulatory circuits using analytical methods he developed from electrical circuits. The idea of studying models of cancer circuitry \u2013 the intricate networks of signaling pathways, gene expression and molecular processes within cell growth and what went wrong in cancer cells \u2013 was compelling.<\/p>\n<p>Then, in 2009, 3D organoids entered oncology and revolutionized the way Shen thought about the potential of cancer research. This new technology allowed researchers to model and manipulate primary patient tissues. This would allow researchers to make precise genomic measurements and then test them in living tissue assays. He decided <a href=\"https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/labs\/xiling-shen-laboratory.html\" target=\"_self\" rel=\"nofollow noopener\">his lab<\/a> would now focus on precision medicine.\u202f<\/p>\n<p>Inside the Shen Lab<\/p>\n<p>After a few years, Shen began to develop cutting-edge engineering and data technology to enable innovative clinical trial designs that get the right drug to the right patient faster. He founded several biotechnology companies that are now working on <a href=\"https:\/\/www.mdanderson.org\/patients-family\/diagnosis-treatment\/clinical-trials.html\" target=\"_self\" rel=\"nofollow noopener\">clinical trials<\/a>. Notably, under his leadership as CEO, one of these companies secured $89 million in Series A financing and was recognized by Business Insider as one of the top 16 life science startups and top 73 overall startups in 2023.\u202fHe has held leadership roles in national cancer research initiatives, including serving as Steering Committee Chair of the National Cancer Institute Patient-Derived Model of Cancer Consortium, co-chair of the NCI Tissue Engineering Collaborative, and Cancer Track Chair of the Biomedical Engineering Society Meeting.\u202f<\/p>\n<p>In June 2024, Shen brought his lab and his work to MD Anderson as a Cancer Prevention and Research Institute of Texas (<a href=\"https:\/\/www.mdanderson.org\/newsroom\/CPRIT-awards-MD-Anderson-over-29-million-for-prevention-efforts-cancer-research-and-faculty-recruitment.h00-159781179.html\" target=\"_self\" rel=\"nofollow noopener\">CPRIT<\/a>) scholar.<\/p>\n<p>\u201cI came to MD Anderson to make more bench-to-bedside impact,\u201d he says. \u201cI was impressed by how forward-thinking MD Anderson\u2019s leadership and clinicians are, and how willing they are to try new ideas to improve patient care. Here, everything is patient-focused.\u201d<\/p>\n<p>Today, Shen is a professor of Gastrointestinal Medical Oncology \u2013 Research. He runs a lab that is developing innovative technologies and exploring precision medicine through a systems biology approach with an emphasis on cancer, stem cells and the gut-brain axis \u2013 that is, the bidirectional communication network between the gastrointestinal tract and the central nervous system.<\/p>\n<p>Serving cancer patients<\/p>\n<p>Now, Shen is helping many patients like his uncle. In addition to killing cancer cells, he has developed a new neuromodulation therapy to treat cachexia, a common cancer comorbidity that impacted his uncle. Cachexia causes significant weight and muscle loss and contributes to one-third of cancer deaths, as there currently is no treatment available for it.<\/p>\n<p>Every up, down and swerve of experience helped bring Shen to where he is today, and he\u2019s using that experience to help patients live longer, healthier lives.<\/p>\n<p>\u201cI came to MD Anderson as a bioengineer because of its unparalleled ability to translate discovery from bench to bedside,\u201d Shen says.\u00a0 \u201cAccess to patient samples and records enabled us to identify the most effective targets, and MD Anderson\u2019s multidisciplinary care teams provided the guidance needed to design this unconventional device trial and launch it here \u2013 all to directly benefit cancer patients.\u201d<\/p>\n<p><a href=\"https:\/\/jobs.mdanderson.org\/creative\/careers-research\" target=\"_self\" rel=\"nofollow noopener\">Learn about research careers at MD Anderson<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Xiling Shen, Ph.D., was an electrical engineering professor when a landmark discovery prompted him to shift the focus&hellip;\n","protected":false},"author":2,"featured_media":111682,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[1145,1147,44000,1142,56,58,57,1148,858,2822,49546],"class_list":{"0":"post-111681","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-houston","8":"tag-caregivers","9":"tag-clinical-trials","10":"tag-colorectal-cancer","11":"tag-family-friends","12":"tag-houston","13":"tag-houston-headlines","14":"tag-houston-news","15":"tag-patients","16":"tag-research","17":"tag-survivors","18":"tag-targeted-therapy"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/111681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=111681"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/111681\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/111682"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=111681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=111681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=111681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}